Quarterly report pursuant to Section 13 or 15(d)

Savant Arrangements (Details)

v3.7.0.1
Savant Arrangements (Details) - USD ($)
3 Months Ended 12 Months Ended
Feb. 29, 2016
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Payments for in process research and development       $ 262,500  
Legal expenses       802,000  
Warrant expense included in research and development expenses   $ 28,000   361,000  
Research and development   2,669,000 $ 1,704,000    
Savant Neglected Diseases, LLC [Member]          
Monthly payment amount $ 87,500        
Payments for in process research and development 500,000 2,687,500     $ 250,000
Initial payment amount $ 3,000,000 2,500,000      
Legal expenses   $ 100,000      
Number of shares called by warrant 200,000 200,000      
Exercise price of warrant $ 2.25 $ 2.25      
Milestone payments and certain other contingent payments   $ 21,000,000      
Exercise period of warrant 5 years 5 years      
Fair value of warrants   $ 670,000      
Warrant expense included in research and development expenses   $ 87,500      
Research and development       $ 3,250,000  
Savant Neglected Diseases, LLC [Member] | Exercisable Immediately [Member]          
Percentage of warrants exercisable 25.00% 25.00%